In the relatively short window of time in which this technology has been widely available for gene editing applications it has already evolved rapidly to become more powerful.
Here are some new papers of interest on this technology.
With many CRISPR-Cas9 papers every week these days there are probably other great papers too. What are your favorite recent papers in this area lately?
How much off-site targeting is there? Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells. February 9. Nature Methods. Kim D, Bae S, Park J, Kim E, Kim S, Yu HR, Hwang J, Kim JI, Kim JS.
Highly efficient Cas9-mediated transcriptional programming. March 2. Nature Methods. Chavez A, Scheiman J, Vora S, Pruitt BW, Tuttle M, P R Iyer E, Lin S, Kiani S, Guzman CD, Wiegand DJ, Ter-Ovanesyan D, Braff JL, Davidsohn N, Housden BE, Perrimon N, Weiss R, Aach J, Collins JJ, Church GM.
Increased efficiency via inhibiting NHEJ. Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. March 23. Nature Biotechnology. Maruyama T, Dougan SK, Truttmann MC, Bilate AM, Ingram JR, & Ploegh HL. Figure 1a-b above.
Modifying the epigenome. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. April 6. Nature Biotechnology. Hilton IB, D’Ippolito AM, Vockley CM, Thakore PI, Crawford GE, Reddy TE, & Gersbach CA.
Smaller Cas9 yields bigger clinical potential? In vivo genome editing using Staphylococcus aureus Cas9. April 9. Nature. F. Ann Ran, Le Cong, Winston X. Yan, David A. Scott, Jonathan S. Gootenberg, Andrea J. Kriz, Bernd Zetsche, Ophir Shalem, Xuebing Wu, Kira S. Makarova, Eugene V. Koonin, Phillip A. Sharp & Feng Zhang